Synergistic antimicrobial activities of epigallocatechin gallate, myricetin, daidzein, gallic acid, epicatechin, 3-hydroxy-6-methoxyflavone and genistein combined with antibiotics against ESKAPE pathogens

David Buchmann | Nadin Schultze | Julia Borchardt | Inken Böttcher | Katharina Schaufler | Sebastian Guenther

Abstract

Aim: To verify synergistic effects, we investigated the antimicrobial activity of seven phenolic phytochemicals (gallic acid; epicatechin; epigallocatechin gallate; daidzein; genistein; myricetin; 3-hydroxy-6-methoxyflavone) in combination with six antibiotics against multidrug-resistant isolates from the ESKAPE group.

Methods and Results: To investigate single phytochemicals and combinations, initial microdilution and checkerboard assays were used, followed by time-kill assays to evaluate the obtained results. The research revealed that phenolic compounds on their own resulted in little or no inhibitory effects. During preliminary tests, most of the combinations resulted in indifference (134 [71.3%]). In all, 30 combinations led to antagonism (15.9%); however, 24 showed synergistic effects (12.8%). The main tests resulted in nine synergistic combinations for the treatment of four different bacteria strains, including two substances (3-hydroxy-6-methoxyflavone, genistein) never tested before in such setup. Time-kill curves for combinations with possible synergistic effects confirmed the results against Acinetobacter baumannii as the one with the greatest need for research.

Conclusions: The results highlight the potential use of antibiotic–phytocompound combinations for combating infections with multi-resistant pathogens. Synergistic combinations could downregulate the resistance mechanisms of bacteria.

Significance and Impact of the Study: The aim of this study is to demonstrate the potential use of phenolic natural compounds in combination with conventional antibiotics against multidrug-resistant bacteria of the ESKAPE group. Due to synergistic effects of natural phenolic compounds combined with antibiotics, pathogens that are already resistant to antibiotics could be resensitized as we were able to reduce their MICs back to sensitive. In addition, combination therapies could prevent the development of resistance by reducing the dose of antibiotics. This approach opens...
INTRODUCTION

Bacterial infectious diseases are generally treated with antibiotics, but their over- and misuse have promoted a frightening situation of antibiotic resistance around the world. Therefore, and due to a lack of development of new antibiotics, therapeutic options are constantly getting fewer. The U.S. Food and Drug Administration (FDA) approved only six new antibiotics in 2017 (FDA, 2018), four in 2018 (FDA, 2019) and also four in 2019 (FDA, 2020) not one of these belonged to a new class. Linezolid and daptomycin are representatives of the last discovered classes since the 1980s (Durand et al., 2019). In addition to the 41 antibiotic compounds belonging to known classes, currently there is only one compound in the development pipeline that belongs to a new class, namely darobactin (Imai et al., 2019). Although a large proportion (44%) of these substances have the potential to treat infections caused by ESKAPE pathogens, it must be taken into account that only 60% of the substances on phase-III studies will be approved and enter the market (Kim, 2020).

Owed to this predicament, a growing number of infections—such as pneumonia, urinary tract infections, gonorrhoea and salmonellosis—are becoming more difficult to treat as the antibiotics used loose effectiveness. Therefore, the World Health Organization (WHO) declared antibiotic resistance as ‘one of the biggest threats to global health’ (WHO, 2018). Moreover, the medical costs to treat infections caused by resistant bacteria are higher due to longer hospital stays, longer duration of sickness and the use of more expensive drugs (Zhen et al., 2019). For these reasons, research in the field of drug resistance mechanisms and drug development requires actions across all states and societies around the world. For combating the economic burden of antibiotic resistance, the WHO published in 2017 an overviewed global priority list of antibiotic resistant bacteria to guide research, discovery and development of new antibiotics (Tacconelli, 2017). In this list, Acinetobacter baumannii, Pseudomonas aeruginosa as well as Enterobacteriaceae are classified as critical; Enterococcus spp. and Staphylococcus aureus are listed as high priority. These collectively named ESKAPE group are increasingly involved in infectious diseases and are the leading cause of nosocomial infections all over the world (Santajit & Indrawattana, 2016). The difficulty to treat is based on their capability to escape biocidal action of well-known and commonly used antibiotics (Pendleton et al., 2013). Deeper studies on these pathogenic organisms are urgently necessary. Hence, five species from the ESKAPE group were selected for this study.

The study of the activity of natural products is a promising approach since more than 75% of all antimicrobials currently used for the treatment of bacterial infections are natural products or their derivatives (Durand et al., 2019). While most of them were isolated from micro-organisms such as Penicillium notatum or Streptomyces spp. (Barbieri et al., 2017; Clarady et al., 2006; Patridge et al., 2016), many plants have been used to treat human bacterial infections since ancient times due to secondary metabolites they compromise (Barbieri et al., 2017; Rakholiya et al., 2013). This heterogeneous group of chemical compounds has been developed over a long period of time to defend plants from different environmental factors, including bacteria. In addition to alkaloids, sulphur-containing phytochemicals, terpenoids and polyphenols also display antimicrobial activity and have become a focus of research. Phytochemicals often have significantly higher minimal inhibitory concentrations (MICs) compared to the commonly used antibiotics. However, numerous studies demonstrated increasing effectiveness of phyto-compounds as well as synergic activity when combining antibiotics with phytochemicals (Amin et al., 2015; Ayaz et al., 2019; Cho et al., 2011; Cui et al., 2012; Dey et al., 2016; Hemaishwarya et al., 2008; Hu et al., 2001; Lin et al., 2005; Rakholiya et al., 2013; Regueira et al., 2017; Rondevaldova et al., 2018). With the aim to find new promising effective combinations against multidrug-resistant ESKAPE species and to confirm the applicability of phenolic compounds in combined therapies, five antibiotics from different classes were chosen, for combinatorial testing with seven phenolic phytocompounds (epigallocatechin gallate, myricetin, daidzein, genistein, epicatechin, gallic acid and 3-hydroxy-6-methoxylavone). Starting with preliminary testing, the most promising combinations with a potential partial or synergistic effect were selected for further investigation by checkerboard and time-kill assays.

MATERIALS AND METHODS

Chemicals

Investigated phytochemicals were obtained from Carbosynth (Compton), Acros Organics, Alfa Aesar,
ChemFaces and Cayman Chemical. Antibiotics were purchased from VWR, Cayman Chemical, Alfa Aesar, Sigma Aldrich and Carl Roth as shown in Table 1. Stock solutions of antibiotics or phenolic compounds were prepared taking into account the salt concentrations with water, concentrated ethanol (chloramphenicol) or DMSO (phenolic compounds) up to the following concentrations (mg ml\(^{-1}\)): ampicillin (12.8), cefotaxime (6.4), chloramphenicol (12.8), ciprofloxacin (0.4), gentamicin (12.8), tetracycline (12.8), phytochemicals (10.0) and stored at −20°C.

**Bacterial strains**

The different bacterial strains comprise reference strains of major ESKAPE pathogens (A. baumannii ATCC 19606, DSM 9308; E. coli ATCC 25922; S. aureus ATCC 29213; Klebsiella pneumoniae ATCC 700603; P. aeruginosa ATCC 27853) and clinical isolates (MRSA PBIO483; A. baumannii PBIO721; E. coli PBIO730, PBIO1442; K. pneumoniae PBIO1455, PBIO1990; P. aeruginosa PBIO712 and PBIO2208). Their detailed resistance pattern is summarized in Table 2. All strains were stored in cryovials, containing 20% glycerol, at −80°C. Before use, fresh bacterial suspension was prepared from an overnight culture on LB-agar-plates in cation adjusted Müller-Hinton-II medium (MH-II-medium, Carl Roth). The inoculum of one colony in 5 ml medium was incubated at 37°C under shaking conditions (200 rpm) overnight.

**Antimicrobial sensitivity testing**

Preparation and dilution of all solutions were carried out according to Clinical and Laboratory Standards Institute (CLSI) guidelines (CLSI, 2012) and the recommendations of manufacturers.

The MICs were determined by a broth dilution method carried out for 11 natural phenolic compounds and six antibiotics using cation adjusted MH-II-medium. Each experiment was performed in three replicates.

Starting with the antibiotic stock solutions, a serial twofold dilution was performed from row A to row G of the microtiter plates (96 wells, sterile, F, Carl Roth) with the following final concentrations (µg ml\(^{-1}\)): ampicillin (256-4), cefotaxime (128-4), chloramphenicol (256-4), ciprofloxacin (8-0.125), gentamicin (256-4) and tetracycline (256-4). Row H remained without antibiotic as growth control. Ten microliters of inoculum adjusted to an OD 0.05 at 600 nm (biochrom Ultraspec 10) were added to the 90 µl of compound solutions. Tests were conducted in duplicates in columns 2–11, columns 1 and 12 remained without any additions (substances or bacteria). The same procedure was performed for the phenolic compounds starting with 400 µg ml\(^{-1}\). The final concentration of solvent was less than 2% (v/v) and did not affect the bacterial growth. The MIC value was visually assessed and recorded after incubation at 37°C for 24 h. The minimum concentration of compound at which no visible growth occurred was taken as the MIC value.

**Initial testing**

For a preliminary combination testing, the plates contained diluted antibiotics in final concentrations as described above in a total volume of 45 µl. Each well was mixed with 45 µl of a phytocompound solution (889 µg ml\(^{-1}\) in MH-II-medium). An overnight bacterial suspension was set to an optical density (OD) of 0.05, measured by photometer (biochrom Ultraspec 10) at 600 nm. Ten microliters of diluted suspension were filled into the prepared microtiter plates resulting in approx. 10\(^5\) CFU per ml, thus yielded a final volume of 100 µl. In summary, the test wells comprised 400 µg ml\(^{-1}\) of the phenolic substances combined with twofold decreasing antibiotic concentrations. The last well without turbidity after incubation at 37°C for approximately 24 h (depending on species according to the CLSI guidelines) was visually detected as the lowest inhibitory concentration.

**Checkerboard assay**

The possibly existences of synergism or antagonism of the most active combinations reported from the initial testing were examined in more detail using the checkerboard microdilution method (Moody, 2004), according to the Clinical Microbiology Procedures Handbook with slight modifications (Isenberg, 2004). In detail, serial twofold dilutions of the phytochemicals and the antibiotics in combination were processed in 96-well microtiter plates (sterile, F, Carl Roth). Hence, the antibiotic of the combination was diluted vertically from columns 1–9 (resulting concentrations depends on chosen antibiotic) while the phytochemical was pipetted horizontally and diluted from A to F resulting in concentrations between 400 and 12.5 µg ml\(^{-1}\). Ten microliters of bacterial suspension with OD 0.05 were added to the wells containing 90 µl compound combinations, MH-II-medium alone or MH-II-medium with solvent (max. concentration 2% (v/v)).

The plates were covered and closed with parafilm to avoid evaporation and then incubated at 37°C for 24 h. The lowest concentration that inhibits visible growth for each combination was determined.
| Antimicrobial                          | Manufacturer   | Structure | CAS-number |
|--------------------------------------|----------------|-----------|------------|
| Genistein (Gin)                      | Cayman Chemical| ![Genistein structure](image1) | 446-72-0   |
| Daidzein (Da)                        | Alfa Aesar     | ![Daidzein structure](image2)   | 486-66-8   |
| Myricetin (Mry)                      | Carbosynth     | ![Myricetin structure](image3)  | 529-44-2   |
| 3-hydroxy-6-methoxyflavone (6-MF)   | Carbosynth     | ![3-hydroxy-6-methoxyflavone structure](image4) | 93176-00-2 |
| (-)-Epigallocatechin gallate (EGCG) | Cayman Chemical| ![EGCG structure](image5)       | 989-51-5   |
| (-)-Epicatechin (EC)                 | Cayman Chemical| ![EC structure](image6)         | 490-46-0   |
| Gallic acid (GA)                     | Cayman Chemical| ![Gallic acid structure](image7) | 149-91-7   |

(Continues)
The fractional inhibitory concentration index (FICI) was calculated by the following equation:

\[
\frac{A}{\text{MIC } A} + \frac{B}{\text{MIC } B} = \text{FICI}
\]

(1)

In Formula (1), A stands for the MIC of the antibiotic in combination with the phytochemical compound, MIC A corresponds to MIC of the antibiotic alone and the same for B, the phytochemical, respectively. FICI values of 0.5 or less indicate as synergistic activity; as partial synergism, when
FICIs were between 0.5 and 1.0; FICI values up to 2.0 were named as indifferent, whereas values higher than 2.0 were set as antagonism (Cui et al., 2012; Osterburg et al., 2009). The FICIs represent the mean of three independent experiments, whereas in cases of more than one synergistic, partial synergistic or antagonistic combinations always the lowest FICI (indicates the best combination) was selected.

A purity control via plating of 4 µl from random wells on BDTM CHROMagar™ Orientation Medium was performed for one assay of each strain and day to assure that no cross contamination occurred.

**Time-kill assay**

Time-kill assays were performed as described by Jayaraman et al., (2010). Briefly, the best effective combinations obtained in the checkerboard assays were selected and tested against *A. baumannii* (PBIO2202), one of the bacterial species considered by the ‘WHO’s priority list for research and development of new antibiotics’ (Tacconelli, 2017). Tubes filled with MH-II-medium, containing test solutions of single substances with various volumes regarding their test concentrations as well as their solubilities and their combinations, as well as a growth control only with solvents, were prepared. Based on the MICs, sub-inhibitory antibiotic concentrations (approx. ¼ MIC) were tested. Since the highest tested concentration of the phenolics did not result in a detectable MIC, we used ½ of the highest investigated concentration for this assay.

Bacterial suspension was adjusted to OD 0.5 and diluted 1 : 10 in MH-II-medium. The prepared tubes have been inoculated with 150 µl of diluted bacterial suspension resulting in $5 \times 10^5$ CFU per ml in a total volume of 15 ml. Samples were collected at 0, 2, 4, 8 and 24 h and plated on LB agar to count the viable colonies after 24 h of incubation at 37°C.

Synergy effects were declared as more than 100-fold decrease (more than two log$_{10}$ steps) of CFU per ml by the combinations compared to the most active compound alone. An increase of ≥2 log$_{10}$ CFU per ml of surviving cells is defined as antagonism and a counting between is declared as indifferent (Akinyele et al., 2017). Experiments were performed as independent replicates.

**Statistical analysis**

Values are represented as mean ± SD. All analyses were done as three biological independent experiments.

### TABLE 2  Antimicrobial resistances of examined isolates and their origin. * 3/4MRGN classify Gram-negative bacterial isolates into resistance groups if they are resistant to three or all of the following groups of antibiotics: piperacillin as a penicillin derivative, cephalosporin with an extended spectrum, carbapenems and fluoroquinolones (Kaase 2016)

| Strain                        | Database number          | Origin   | Resistances/type strain |
|-------------------------------|--------------------------|----------|-------------------------|
| *Acinetobacter baumannii*     | ATCC 19606 (PBIO2202)    | Human    | Intrinsic/type strain   |
|                               | DSM 9308 (PBIO2212)      | Human    | Intrinsic/type strain   |
|                               | PBIO721                  | Fly      | Intrinsic               |
| *Escherichia coli*            | ATCC 25922 (PBIO904)     | Human    | EUCAST-Ref. strain      |
|                               | PBIO730                  | Blackbird| ESBL                    |
|                               | PBIO1442                 | Human    | ESBL/3MRGN*             |
| *Klebsiella pneumoniae*       | ATCC 700603 (PBIO2010)   | Human    | ESBL/EUCAST-Ref. strain |
|                               | PBIO1455                 | Human    | 3MRGN*                  |
|                               | PBIO1990                 | Human    | 4MRGN*                  |
| *Pseudomonas aeruginosa*      | ATCC 27853 (PBIO903)     | Human    | EUCAST-Ref. strain      |
|                               | PBIO712                  | Fly      | Intrinsic               |
|                               | PBIO2208                 | Human    | Intrinsic               |
| *Staphylococcus aureus*       | ATCC 29213 (PBIO901)     | Human    | EUCAST-Ref. strain      |
|                               | PBIO483                  | Human    | MRSA                    |
RESULTS

Antimicrobial sensitivity test

We investigated the susceptibility of five bacterial strains (Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus aureus), each with three different isolates, against five classes of antibiotics alone and in combination with seven phytochemicals. In accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST), the antibiotic activities based on their MIC were categorized as sensitive, intrinsic resistant and resistant as shown in Table S1. The investigated strains showed different resistance patterns mostly against ampicillin, cefotaxime, chloramphenicol, ciprofloxacin and gentamicin with at least 50% of tested isolates being resistant including intrinsic resistant strains, thereof the most against tetracycline. No bacterial isolate was susceptible to all of the antibiotics investigated.

The phytochemicals alone had no inhibitory effects in tested concentrations (12.5–400 µg ml⁻¹), except epigallocatechin gallate (EGCG) against S. aureus (PBIO483, PBIO901) with a MIC of 200 µg ml⁻¹ (data not shown).

Initial testing

After preliminary testing of one isolate of each strain, it was possible to select interesting combinations with potential partial synergistic effects based on the FICI values. These tests were carried out with a constant concentration of the phenolic compound that was always 400 µg ml⁻¹. According to the equation above, this constant concentration results always in a value of 1 for calculation of summand B (the phytocompound). If you take this into account in Formula 1, additive effects appear in this special test setting when the FICI is between 1 and 1.5 and therefore we regarded these combinations as more interesting for further tests. Combinations of antibiotics and 400 µg ml⁻¹ phytocompound, which were declared indifferent due to bacterial growth up to the MIC of the antibiotic, gave values of 1.5–2. Values higher than 2 determine potential antagonisms due to the bacterial growth above the inhibiting antibiotic concentration alone. In total, there were 24 combinations with FICI values between 1.0 and 1.5, meaning a potential synergism, 30 ensembles showed values above 2.0, representing a possible antagonism, and 134 setups resulted in no changes (see Table S2).

The phytochemical with the most combinatorial hits was epigallocatechin gallate with eight hits followed by 3-hydroxy-6-methoxyflavone with six hits, myricetin with four hits and genistein as well as daidzein with three hits. No potential synergism was observed for epicatechin and gallic acid in any combination nor bacteria tested. Instead, combinations with epicatechin with eight combinatorial hits as well as gallic acid with five hits were mostly antagonistic (see Table S2).

The combination with the broadest spectrum against different bacterial species was epigallocatechin gallate with tetracycline and cefotaxime, respectively, both of which were effective against two different species (A. baumannii and S. aureus or P. aeruginosa). In contrast, chloramphenicol in combination with daidzein showed the most antagonistic effects in different species including E. coli, S. aureus and P. aeruginosa. For E. coli, no finding indicated a synergistic combination while nine test setups implied synergisms for A. baumannii based on FICI values lower than 1.5 (see Table S2).

Checkerboard assay

Based on the initial testing, various combinations were picked for further confirming investigations using checkerboard assays. These assays were performed including additional multi-resistant isolates of the tested species. Four of six investigated combinations against A. baumannii PBIO2202 yielded FICI below 0.5, which is declared as synergism. The tested combinations against A. baumannii isolates PBIO721 and 2212 led to decreased amounts of antibiotics as well, the FICI being between 0.46 and 1.5, 1.63 was obtained once (Table 3). Especially, the concentrations needed for an inhibitory effect of cefotaxime, gentamicin and tetracycline could be reduced in combination with epigallocatechin gallate. For example, on average, the use of cefotaxime could be lowered from 128 to 32 µg ml⁻¹ together with 100 µg ml⁻¹ epigallocatechin gallate, for gentamicin from 27 to 8 µg ml⁻¹ in combination with 50 µg ml⁻¹ and for tetracycline the addition reduced the MIC from 8 to 3.3 or 4.7 µg ml⁻¹ with epigallocatechin gallate or myricetin. The combination with genistein or daidzein decreased the needed gentamicin on average from 27 to 4 and 8 µg ml⁻¹, respectively (Table 3).

Comparable data were generated with the combinations of ciprofloxacin with epigallocatechin gallate and tetracycline with epigallocatechin gallate or myricetin against P. aeruginosa. No explored combination yielded in FICI lower than 0.5, but all test setups resulted in values between 0.52 and 1.56. While they ranged between 0.53 and 0.77 for PBIO903, the values of 1.31–1.56 could be calculated for PBIO712 and PBIO2208 in two of six cases (Table 3). These FICI mean, it was possible to reduce the antibiotic MIC from 0.29 to 0.10 µg ml⁻¹ (Cip+EGCG)
| Components | MIC (µg ml⁻¹) | MICₐ (µg ml⁻¹) | FIC index (interpretation) | MIC (µg ml⁻¹) | MICₐ (µg ml⁻¹) | FIC index (interpretation) | MIC (µg ml⁻¹) | MICₐ (µg ml⁻¹) | FIC index (interpretation) |
|------------|---------------|----------------|---------------------------|---------------|----------------|---------------------------|---------------|----------------|--------------------------|
| A. baumannii (PBIO721) | | | | | | | | | |
| Tet | 3 | 2 | 1.17 (I) | 8 | 3.3 | 0.48 (S) | 7 | 4 | 0.70 (P) |
| EGCG | 400 | 200 | | 400 | 25 | | 400 | 50 | |
| Tet | 3 | 3 | 1.13 (I) | 8 | 4.7 | 0.84 (P) | 7 | 7 | 1.5 (I) |
| Myr | 400 | 50 | | 400 | 100 | | 400 | 200 | |
| Gent | 3 | 1 | 0.58 (P) | 27 | 4 | 0.65 (P) | 43 | 9 | 0.46 (S) |
| EGCG | 400 | 100 | | 400 | 200 | | 400 | 100 | |
| Gent | 3 | 3 | 1.25 (I) | 27 | 4 | 0.40 (S) | 43 | 32 | 0.87 (P) |
| Gin | 400 | 100 | | 400 | 100 | | 400 | 50 | |
| Gent | 3 | 2 | 0.92 (P) | 27 | 8 | 0.42 (S) | 43 | 27 | 1.63 (I) |
| Da | 400 | 100 | | 400 | 50 | | 400 | 400 | |
| Cef | 16 | 8 | 0.63 (P) | 128 | 32 | 0.50 (S) | 7 | 4.7 | 0.92 (P) |
| EGCG | 400 | 50 | | 400 | 100 | | 400 | 100 | |
| Pseudomonas aeruginosa (PBIO712) | | | | | | | | | |
| Tet | 53 | 27 | 0.76 (P) | 64 | 32 | 0.53 (P) | 48 | 26.7 | 1.06 (I) |
| EGCG | 400 | 100 | | 400 | 12.5 | | 400 | 200 | |
| Tet | 53 | 27 | 1.01 (I) | 64 | 32 | 0.63 (P) | 48 | 26.7 | 1.56 (I) |
| Myr | 400 | 200 | | 400 | 50 | | 400 | 400 | |
| Cip | 0.13 | 0.04 | 1.31 (I) | 0.25 | 0.13 | 0.77 (P) | 0.5 | 0.125 | 0.75 (P) |
| EGCG | 400 | 400 | | 400 | 100 | | 400 | 200 | |
| Klebsiella pneumoniae (PBIO1455) | | | | | | | | | |
| Tet | 11 | 4 | 0.49² (S) | 13 | 7 | 0.66 (P) | 13 | 10.7 | 1.32 (P) |
| EGCG | 400 | 50 | | 400 | 50 | | 400 | 200 | |
| Tet | 11 | 3.3 | 0.43 (S) | 13 | 13 | 2 (I) | 13 | 8 | 0.74 (P) |
| Myr | 400 | 50 | | 400 | 400 | | 400 | 50 | |
| Cip | 8 | 8 | 2 (I) | 8 | 8 | 2 (I) | 0.3 | 0.17 | 0.82 (P) |
| EGCG | 400 | 400 | | 400 | 400 | | 400 | 100 | |
| Cip | 8 | 6.7 | 1.34 (I) | 8 | 8 | 2 (I) | 0.3³ | 0.25 | 0.86 (P) |
| Myr | 400 | 200 | | 400 | 400 | | 400 | 12.5 | |

(Continues)
| Components | MIC (µg ml⁻¹) | MICc (µg ml⁻¹) | FIC index (interpretation) | MIC (µg ml⁻¹) | MICc (µg ml⁻¹) | FIC index (interpretation) | MIC (µg ml⁻¹) | MICc (µg ml⁻¹) | FIC index (interpretation) |
|------------|--------------|----------------|---------------------------|--------------|----------------|---------------------------|--------------|----------------|---------------------------|
| Amp        | 256†         | 17.3           | 0.32 (S)                  | 32           | 5.3            | 0.29 (S)                  |              |                |                           |
| EGCG       | 200          | 50             |                           | 200          | 25             |                           |              |                |                           |
| Amp        | 256†         | 53.3           | 0.46 (S)                  | 32           | 12             | 0.50 (S)                  |              |                |                           |
| Myr        | 400          | 100            |                           | 400          | 50             |                           |              |                |                           |
| Amp        | 256†         | 64             | 0.75 (P)                  | 32           |                | n.a.                      |              |                |                           |
| Gin        | 400          | 200            |                           | 400          |                |                           |              |                |                           |
| Chlor      | 19†          | 4              | 0.46 (S)                  | 32†          | 8              | 0.50 (S)                  |              |                |                           |
| EGCG       | 200          | 50             |                           | 200          | 50             |                           |              |                |                           |
| Chlor      | 19†          | 4.7            | 0.75 (P)                  | 32†          | 26.7           | 1.83 (I)                  |              |                |                           |
| Myr        | 400          | 200            |                           | 400          | 400            |                           |              |                |                           |
| Cef        | 8†           | 4              | 0.53 (P)                  | 1            | 0.5            | 0.63 (P)                  |              |                |                           |
| 6-MF       | 400          | 12.5           |                           | 400          | 50             |                           |              |                |                           |
| Cef        | 8†           | 1              | 0.25 (S)                  | 1            | 0.5            | 0.65² (P)                 |              |                |                           |
| EGCG       | 200          | 25             |                           | 200          | 25             |                           |              |                |                           |

Values are shown as mean of three (except stated differently). Classification according to EUCAST description: † = resistant; ‡ = intrinsic resistant; * = intermediate; # = susceptible; n.a. = not available; ¹ according to CLSI-Guideline. MIC = minimal inhibitory concentration of compounds alone; MICc = minimal inhibitory concentration of components in combination; S = synergism; P = partial synergism; I = indifferent; ² n = 2.
as well as from 51.7 to 28.6 µg ml\(^{-1}\) (Tet+EGCG or Myr) across all tested strains.

*Klebsiella pneumoniae* could also be influenced significantly by the use of antibiotics together with epigallocatechin gallate or myricetin. The FICI ranged between 0.43 and 2, while two combinations led to synergism, five showed FICI between 0.66 and 0.86, five test setups showed neither antagonism nor synergism (Table 3). The composite of tetracycline and epigallocatechin gallate was effective against all isolates and decreased antibiotic MIC, on average from 12.3 to 7.2 µg ml\(^{-1}\). The combinations ciprofloxacin plus epigallocatechin gallate or myricetin were nearly ineffective, especially against the highly resistant isolates PBIO1455 and 990.

The strongest effects of combinations of antibiotic with phenolic substances could be achieved in *S. aureus*. Altogether, four out of seven tested combinations were synergistic against PBIO483 as well as three out of six against PBIO901 namely ampicillin plus epigallocatechin gallate or myricetin, chloramphenicol plus epigallocatechin gallate as well as cefotaxime plus epigallocatechin gallate (not for PBIO901) (Table 3).

In particular, the concentrations of beta lactams and ciprofloxacin could be reduced by more than 90% and 79%, respectively, in combination with epigallocatechin gallate. Tested combinations of antibiotic and myricetin as well as 3-hydroxy-6-methoxyflavone were also effective but much less than the composites with epigallocatechin gallate.

Overall, the test setups against *E. coli* isolates, not one combination, had a noteworthy effect on the decrease of antibiotic MIC.

**Time-kill curves**

Since *A. baumannii* is a strain with high priority for research and development of antimicrobial drugs around the world, time-kill curves were also performed with combinations that showed positive results in the checkerboard assay. Nor the antibiotic neither the phenolic substance alone showed any significant reduction of CFU per ml (>2 log\(_{10}\)) compared to the control after 24 h incubation. However, there was a decrease in the number of bacteria noticeable during an incubation period of 4 h and 8 h or 8 h and 24 h when *A. baumannii* was treated with antibiotics alone (Figure 1). The combination of cefotaxime and epigallocatechin gallate led to 1–2 log\(_{10}\) reduction of viable cells at 24 h compared to the compounds alone (Figure 1a). The synergistic effects of gentamicin and epigallocatechin gallate were more pronounced. There was a subsequent decrease in CFU per ml over time. After just 8 h, there was a >2 log\(_{10}\) reduction of the bacterial count, which reached its maximum at 24 h with a 5–6 log\(_{10}\) decrease (Figure 1b).

**DISCUSSION**

Due to the increasing bacterial resistance spreading worldwide and the lack of development of new antibiotic classes or antimicrobial substances, new strategies to combat bacterial diseases are necessary. One option lies in the combination of either antibiotics among themselves or antibiotics with phytochemicals to exploit potential synergistic effects. It is reported that plants and their extracts provide inhibitors against pathogens. Hence, this study focused on phytochemicals seven of which have yet to be investigated, and used in combinations with established antibiotics to be used against highly resistant bacteria, which are known to be responsible for nosocomial or urinary tract infections. These infections are complicated to treat, which results in an urgent need for new treatment strategies (Pendleton et al., 2013; Santajit & Indrawattana, 2016).

Based on this fact, for the investigation, the so-called ESKAPE strains, except *Enterococcus faecalis*, were chosen, each with three resistant isolates and tested against five different classes of antibiotics combined with seven
phytochemicals. After an initial testing, the most interesting combinations were selected. These included six different combinations of substances for *A. baumannii*, four for *K. pneumoniae*, three for *P. aeruginosa* and seven for *S. aureus*. Although there was not one positive initial tested antibiotic–phenolic compound combination for *E. coli*, 12 test setups were examined by checkerboard assays because of particularly relevant treatment needs of *E. coli* infections.

It could be confirmed that combinations of antibiotics with secondary plant compounds, particularly epigallocatechin gallate, are often associated with decreased MIC for the antibiotics in multiple bacterial strains, for example *P. aeruginosa* or *A. baumannii* as well as *K. pneumoniae* or *S. aureus*, as previously described (Jayaraman et al., 2010; Lee et al., 2017; Liu et al., 2019; Sudano Roccaro et al., 2004).

Altogether, strains of two species (*A. baumannii* and *S. aureus*) could be reclassified in our experiments from EUCAST classification ‘Resistant’ to ‘Susceptible’, one strain (*K. pneumoniae*) could be influenced from ‘Susceptible, increased exposure’ to ‘Susceptible’ and *P. aeruginosa* switched from ‘Resistant’ to ‘Susceptible, increased exposure’ by treating with antibiotic–phenolic compound combinations (The European Committee on Antimicrobial Susceptibility Testing., 2020). The potent combinations, as shown in Table 4, were gentamicin plus epigallocatechin gallate, daidzein or genistein, respectively, against *A. baumannii*, chloramphenicol together with epigallocatechin gallate as well as myricetin against *S. aureus* and ciprofloxacin combined with epigallocatechin gallate or myricetin against ESBL-producing *K. pneumoniae* and *P. aeruginosa*. However, this combination did not work for the highly resistant carbapenemase-producing *K. pneumoniae* isolates PBIO1455 and PBIO1990.

The strongest effect on the reduction of used antibiotic could be generated by treatment of *S. aureus*, even though the strain is a multidrug-resistant MRSA. The obtained FICI values reached down to 0.2 and were calculated for four combinations as synergism. Additionally, there was not one combination without any growth inhibition effect. Surprisingly, in this study, no additional effects between ciprofloxacin and pre-tested phytocompounds were detectable, in contrast to Abreu et al., (2017). That might be owed to differences in genetic determinants of the strains. Instead, it was observable that the phytocompounds improved the efficacy of beta lactams as well as the efficacy of chloramphenicol. This may be contributed by increased interruption of cell wall based on inhibition of transpeptidation by beta lactams coupled with potential inhibition of efflux systems such as the efflux pump NorA as described by Braga et al., (2005) for alkaloids as well as downregulation of beta lactamases through phenolic compounds

### Table 4

| Species            | Tested antibiotic | Antibiotic—natural compound combination | EUCAST classification | Changed EUCAST classification |
|--------------------|-------------------|----------------------------------------|-----------------------|-------------------------------|
| *Acinetobacter baumannii* | Gentamicin       | Gentamicin + EGCG                       | Susceptible           | 100-200                       |
|                    |                   | Gentamicin + daidzein                  | Susceptible           | 50-100                        |
|                    |                   | Gentamicin + genistein                 | Susceptible           | 100                           |
| *Staphylococcus aureus* | Chloramphenicol  | Chloramphenicol + EGCG                 | Susceptible           | 50                            |
|                    |                   | Chloramphenicol + myricetin            | Susceptible           | 200                           |
| *Klebsiella pneumoniae* | Ciprofloxacin    | Ciprofloxacin + EGCG                   | Susceptible, increased exposure | 12.5                          |
|                    |                   | Ciprofloxacin + myricetin              | Susceptible           | 200                           |
| *Pseudomonas aeruginosa* | Ciprofloxacin    | Ciprofloxacin + EGCG                   | Susceptible, increased exposure | 200                           |
Especially, epigallocatechin gallate enhanced the penetration of small molecules because of disruption of cell wall synthesis (Zhao et al., 2001). The same mechanisms could be assumed for myricetin and genistein because of their structural similarity.

Multiple synergistic inhibition could be observed for K. pneumoniae by treatment of tetracycline combined with epigallocatechin gallate or myricetin, noteworthy even against highly resistant isolates. Recent studies reported a synergistic behaviour due to changing the capsule structure of K. pneumoniae as well as inhibition of efflux pumps from the resistance-nodulation-cell division (RND)-family (AcrAB) by epigallocatechin gallate (Dey et al., 2016; Mazzariol et al., 2002). Both mechanisms are able to increase bactericidality of tetracycline, because of intracellular accumulation and could explain the enhanced susceptibility of different bacterial strains expressing RND-efflux pumps.

Another noteworthy result should be mentioned is that tetracycline combined with epigallocatechin gallate and myricetin successfully inhibited the growth of intrinsically resistant strains. Pseudomonas aeruginosa as only a third of the initially used antibiotic amount was necessary when phenolic compounds were added. By expression of efflux pump systems, namely the AcrAB-TolC as a part of the RND-family, P. aeruginosa is naturally resistant against tetracycline treatment (Gibbons, 2008). Since P. aeruginosa has efflux pumps from RND-family, it seemed to be that the previously described mechanisms could also apply to this strain. Because of structural similarity to epigallocatechin gallate, the same mode of action could be possible for myricetin.

Comparable observations could be obtained by the treatment of A. baumannii, also a highly intrinsic resistant Gram-negative bacterium. A reduction of almost 70% of tetracycline use, as well as 75% of cefotaxime was detectable combined with epigallocatechin gallate. Furthermore, for the aim of investigating combined influences against ESKAPE strains completely, new substances such as daidzein or genistein were found as active additives with antibiotics. Often these substances showed reduced bacterial growth without FICI being declared as synergistic, but partial synergistic (0.5 ≤ FICI ≤ 1.0).

With this investigation, it could be confirmed that epigallocatechin gallate behaved synergistic together with beta lactams (EGCG + Cef) in accordance with Lee et al (2017). This research as well as others (Nakayama et al., 2013, 2015; Osterburg et al., 2009; Pannek et al., 2006) found synergisms of carbapenems and epigallocatechin gallate against resistant strains by targeting again, a RND-type tripartite efflux pump, named AdeABC. Since daidzein and genistein share structural similarities with epigallocatechin gallate, the obtained results could be explained. However, the retained ineffectiveness of ampicillin in any combination against A. baumannii is not affected by this assumption. Normally, an increased bactericidal effect should apply for ampicillin, as it penetrates through the damaged cell wall just like cefotaxime. Both are inactivated by a beta lactamate, which is the oxacilllinase, a class D carbapenemase, in A. baumannii. Therefore, it could be suggested that the tested phyto compounds may not affect beta lactam enzymes in A. baumannii in the same way.

Additionally, these investigations revealed noticeably more synergistic phyto compound–antibiotic combinations against A. baumannii than against the other tested Gram-negative bacterial strains. This could due to different expression of efflux pumps (Fernández & Hancock, 2012) and their differing inhibition intensities, as well as target affinity of the phyto compounds according to the explained mode of actions above. Pumps, only present in A. baumannii are, for example, AbeM (multidrug and toxic compound extrusion) and AdeABC (resistance-nodulation-cell division) which mediates resistances against aminoglycosides, fluoroquinolones and other. Considering that gentamycin showed the most synergistic effects with phyto compounds, it can be speculated that the AbeM and AdeABC pumps have a special role in the synergistic effects. Besides, A. baumannii shows a widespread intrinsic resistance against antibiotics due to a low number of influx systems, such as porins, which also do not exist in other Gram-negative bacteria. Due to the difficulty of penetrating antibiotics, the loss of porins leads to resistances, for example against carbapenems via CarO (Limansky et al., 2002). Therefore, future investigations should focus on whether and by which phyto compounds these multidrug resistance mechanisms could be reversed either by inhibition of efflux pumps and, for example, beta lactamases or even by stimulation of specific porins.

The thesis of affecting especially efflux and influx systems by phyto compounds is affirmed by the fact that the substances alone show either no or little bactericidal effects.

Moreover, it was unfortunately impossible to find a combination between antibiotic and phytochemical that inhibits E. coli, which is contrary to recent publications. Cui et al. found epigallocatechin gallate and cefotaxime as a synergistic combination. They suggested that exogenous and endogenous reactive oxygen species are responsible for the synergistic effects of epigallocatechin gallate and beta lactams, examined with cefotaxime, because of additive disturbance of the cell wall (Cui et al., 2012). However, the results could be obtained only with nontherapeutically relevant amounts of EGCG (1.5 mg mL⁻¹).

Current practice that is also used in this investigation is assessing the synergistic or antagonistic effects of substance combinations with calculation of fractional inhibitory concentration values (equation above). Unfortunately, this
procedure is directly dependent on chosen start concentrations for bacterial susceptibility testing. That means, if a higher, mostly clinically negligible, test concentration is chosen, the resulting FICI values decrease substantially, therefore seeming to be significantly synergistic. This could also be one reason, why the results of some combinatorial testing in this study are not in accordance with the findings in the literature.

With this investigation it could be shown that different, but structurally similar phenolic substances in combination with antibiotics can inhibit bacterial growth. However, it was not possible to observe which structural elements are required for bactericidal synergisms with antibiotics in detail. Based on previous publications (Cho et al., 2011; Cui et al., 2012; Hu et al., 2001; Isogai et al., 2001; Lee et al., 2017) and the confirmation in this study epigallocatechin gallate turns out as a strong synergistic phytochemical in combination with different antibiotic classes against many bacterial strains. The achieved data led to the hypothesis that a substituent in position two of the flavonol scaffold is necessary, preferably a gallate residue. That is because positive outcomes could often be yielded for myricetin, whereas for genistein or daidzein (compounds without reductions of structural complexity as presented by epicat-

in combination with pomegranate extract and antibiotics against Staphylococcus aureus. BMC Complementary and Alternative Medicine, 15(1), 1–59.

Amin, M.U., Khurram, M., Khattak, B. & Khan, J. (2015) Antibiotic additive and synergistic action of rutin, morin and querce-
inhibitory effect of rutin against methicillin resistant Staphylococcus aureus. BMC Complementary and Alternative Medicine, 15(1), 1–59.

Ayaz, M., Ullah, F., Sadiq, A., Ullah, F., Ovais, M., Ahmed, J. et al. (2019) Synergistic interactions of phytochemicals with antimicrobial agents: potential strategy to counteract drug resistance. Chemico-Biological Interactions, 308, 294–303.

Barbieri, R., Coppo, E., Marchese, A., Daglia, M., Sobarzo-Sánchez, E., Nabavi, S.F. et al. (2017) Phytochemicals for human disease: an update on plant-derived compounds antibacterial activity. Microbiological Research, 196, 44–68.

Braga, L.C., Leite, A.A.M., Xavier, K.G.S., Takahashi, J.A., Bemquerer, M.P., Chartone-Souza, E. et al. (2005) Synergistic interaction between pomegranate extract and antibiotics against Staphylococcus aureus. Canadian Journal of Microbiology, 51, 541–547.

Cho, Y.-S., Oh, J.J. & Oh, K.-H. (2011) Synergistic anti-bacterial and proteomic effects of epigallocatechin gallate on clinical isolates of imipenem-resistant Klebsiella pneumoniae. Phytomedicine, 18, 941–946.

Clardy, J., Fischbach, M.A. & Walsh, C.T. (2006) New antibiotics from bacterial natural products. Nature Biotechnology, 24, 1541–1550.

CLSI (2012) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard-Ninth Edition, CLSI document M07-A9. Wayne, PA: Clinical and Laboratory Standards Institute.

Cui, Y., Kim, S.H., Kim, H., Yeom, J., Ko, K., Park, W. et al. (2012) AFM probing the mechanism of synergistic effects of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) with cefotaxime against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. PLoS One, 7, 1–6.

Dey, D., Ghosh, S., Ray, R. & Hazra, B. (2016) Polyphenolic secondary metabolites synergize the activity of commercial antibiotics against clinical isolates of β-Lactamase-producing Klebsiella pneumoniae. Phytotherapy Research, 30, 272–282.

Durand, G., Raoul, D. & Dubourg, G. (2019) Antibiotic discovery: history, methods and perspectives. International Journal of Antimicrobial Agents, 53, 371–382.

FDA (2018) 2017 new drug therapy approvals. https://www.fda.gov/files/aboutfda/published/2017-New-Drug-Therapy-Approvals-Report.pdf

FDA (2019) 2018 new drug therapy approvals. https://wayback.archive-it.org/7993/20190423191853/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm629241.htm

FDA (2020) New drug therapy approvals 2019. https://www.fda.gov/drugs/new-drugs-fda-cdernew-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2019

Fernández, L. & Hancock, R.E.W. (2012) Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clinical Microbiology Reviews, 25, 661–681.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT
The data supporting the findings of this study are available in the supplementary material to this article.

ACKNOWLEDGEMENT
Open Access funding enabled and organized by Projekt DEAL.

ORCID
David Buchmann https://orcid.org/0000-0001-8523-7696

REFERENCES
Abreu, A.C., Coqueiro, A., Sultan, A.R., Lemmens, N., Kim, H.K., Verpoorte, R. et al. (2017) Looking to nature for a new concept in antimicrobial treatments: isoflavonoids from Cytisus striatus as antibiotic adjuvants against MRSA. Scientific Reports, 7, 3777:1–3777:16.

Akinseye, T.A., Igbinoso, E.O., Akinpelu, D.A. & Okoh, A.I. (2017) In vitro assessment of the synergism between extracts of Cocos nucifera husk and some standard antibiotics. Asian Pacific Journal of Tropical Medicine, 7, 306–313.

Amin, M.U., Khurram, M., Khattak, B. & Khan, J. (2015) Antibiotic additive and synergistic action of rutin, morin and querce-
inhibitory effect of rutin against methicillin resistant Staphylococcus aureus. BMC Complementary and Alternative Medicine, 15(1), 1–59.

Ayaz, M., Ullah, F., Sadiq, A., Ullah, F., Ovais, M., Ahmed, J. et al. (2019) Synergistic interactions of phytochemicals with antimicrobial agents: potential strategy to counteract drug resistance. Chemico-Biological Interactions, 308, 294–303.

Barbieri, R., Coppo, E., Marchese, A., Daglia, M., Sobarzo-Sánchez, E., Nabavi, S.F. et al. (2017) Phytochemicals for human disease: an update on plant-derived compounds antibacterial activity. Microbiological Research, 196, 44–68.

Braga, L.C., Leite, A.A.M., Xavier, K.G.S., Takahashi, J.A., Bemquerer, M.P., Chartone-Souza, E. et al. (2005) Synergistic interaction between pomegranate extract and antibiotics against Staphylococcus aureus. Canadian Journal of Microbiology, 51, 541–547.

Cho, Y.-S., Oh, J.J. & Oh, K.-H. (2011) Synergistic anti-bacterial and proteomic effects of epigallocatechin gallate on clinical isolates of imipenem-resistant Klebsiella pneumoniae. Phytomedicine, 18, 941–946.

Clardy, J., Fischbach, M.A. & Walsh, C.T. (2006) New antibiotics from bacterial natural products. Nature Biotechnology, 24, 1541–1550.

CLSI (2012) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard-Ninth Edition, CLSI document M07-A9. Wayne, PA: Clinical and Laboratory Standards Institute.

Cui, Y., Kim, S.H., Kim, H., Yeom, J., Ko, K., Park, W. et al. (2012) AFM probing the mechanism of synergistic effects of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) with cefotaxime against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. PLoS One, 7, 1–6.

Dey, D., Ghosh, S., Ray, R. & Hazra, B. (2016) Polyphenolic secondary metabolites synergize the activity of commercial antibiotics against clinical isolates of β-Lactamase-producing Klebsiella pneumoniae. Phytotherapy Research, 30, 272–282.

Durand, G., Raoul, D. & Dubourg, G. (2019) Antibiotic discovery: history, methods and perspectives. International Journal of Antimicrobial Agents, 53, 371–382.

FDA (2018) 2017 new drug therapy approvals. https://www.fda.gov/files/aboutfda/published/2017-New-Drug-Therapy-Approvals-Report.pdf

FDA (2019) 2018 new drug therapy approvals. https://wayback.archive-it.org/7993/20190423191853/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm629241.htm

FDA (2020) New drug therapy approvals 2019. https://www.fda.gov/drugs/new-drugs-fda-cdernew-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2019

Fernández, L. & Hancock, R.E.W. (2012) Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clinical Microbiology Reviews, 25, 661–681.
Gibbons, S. (2008) Phytochemicals for bacterial resistance – strengths, weaknesses and opportunities. *Planta Medica*, 74, 594–602.

Hemaiswarya, S., Kruthiventi, A.K. & Doble, M. (2008) Synergism between natural products and antibiotics against infectious diseases. *Phytochemistry*, 15, 639–652.

Hu, Z.-Q., Zhao, W.-H., Hara, Y. & Shimamura, T. (2001) Epigallocatechin gallate synergy with ampicillin/sublactam against 28 clinical isolates of methicillin-resistant *Staphylococcus aureus*. *Journal of Antimicrobial Chemotherapy*, 48, 361–364.

Imai, Y., Meyer, K.J., Iinishi, A., Favre-Godal, Q., Green, R., Manuse, S. et al. (2019) A new antibiotic selectively kills Gram-negative pathogens. *Nature*, 576, 459–464.

Isenberg, H.D. (ed.) (2004) *Clinical microbiology procedures handbook*, 2nd edition. Washington, DC: ASM Press.

Isogai, E., Isogai, H., Hirose, K., Hajashi, S. & Oguma, K. (2001) In vivo synergy between green tea extract and levofloxacin against enterohemorrhagic *Escherichia coli* O157 infection. *Journal of Microbiology*, 42, 248–251.

Jayaraman, P., Sakankar, M.K., Lim, C.S., Tang, T.H. & Sakankar, K.R. (2010) Activity and interactions of antibiotic and phytochemical combinations against *Pseudomonas aeruginosa* in vitro. *Int J Biol Sci*, 6, 556–568.

Kaase, M. (2016) MRGN: new classification for multidrug-resistant Gram-negative pathogens. *LaboratoriumsMedizin*, 37. http://dx.doi.org/10.1515/labmed-2014-0004

Kim, W. (2020) Tracking the global pipeline of antibiotics in development, April 2020. https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2020/04/tracking-the-global-pipeline-of-antibiotics-in-development

Lee, S., Razgan, G.S.A. & Kwon, D.H. (2017) Antibacterial activity of epigallocatechin-3-gallate (EGCG) and its synergism with β-lactam antibiotics sensitizing carbapenem-associated multidrug resistant clinical isolates of *Acinetobacter baumannii*. *Phytomedicine*, 24, 49–55.

Limansky, A.S., Mussi, M.A. & Viale, A.M. (2002) Loss of a 29-kilodalton outer membrane protein in *Acinetobacter baumannii* is associated with imipenem resistance. *Journal of Clinical Microbiology*, 40, 4776–4778.

Lin, R.-D., Chin, Y.-P. & Lee, M.-H. (2005) Antimicrobial activity of antibiotics in combination with natural flavonoids against clinical extended-spectrum beta-lactamase (ESBL)-producing *Klebsiella pneumoniae*. *Phytotherapy Research*, 19, 612–617.

Liu, C., Huang, H., Zhou, Q., Liu, B., Wang, Y., Li, P. et al. (2019) Antibacterial and antibiotic synergistic activities of the extract from *Pithecellobium clupearia* against clinically important multidrug-resistant gram-negative bacteria. *European Journal of Integrative Medicine*, 32, 100996–101029.

Mazzariol, A., Zuliani, J., Cornaglia, G., Rossolini, G.M. & Fontana, R. (2002) AcrAB efflux system: expression and contribution to fluoroquinolone resistance in *Klebsiella spp*. *Antimicrobial Agents and Chemotherapy*, 46, 3984–3986.

Miklasinska-Majdanik, M., Kepa M., Wojtyczka R., Idzik D. & Wąsik T. (2018) Phenolic compounds diminish antibiotic resistance of *Staphylococcus aureus* clinical strains. *International Journal of Environmental Research and Public Health*, 15, 2321. http://dx.doi.org/10.3390/ijerph15102321

Moody, J. (2004) Synergism testing: broth microdilution checkerboard and broth macrodilution methods. In Isenberg, H.D. (Ed.) *Clinical microbiology procedures handbook*, 2nd edition, pp. 877–900. Washington, DC: ASM Press.

Nakayama, M., Shimatani, K., Ozawa, T., Shigemune, N., Tomiyama, D., Yui, K. et al. (2015) Mechanism for the antibacterial action of epigallocatechin gallate (EGCg) on *Bacillus subtilis*. *Bioscience, Biotechnology, and Biochemistry*, 79, 845–854.

Nakayama, M., Shimatani, K., Ozawa, T., Shigemune, N., Tsugukuni, T., Tomiyama, D. et al. (2013) A study of the antibacterial mechanism of catechins: isolation and identification of *Escherichia coli* cell surface proteins that interact with epigallocatechin gallate. *Food Control*, 33, 433–439.

Osterburg, A., Gardner, J., Hyon, S.H., Neely, A. & Babcock, G. (2009) Highly antibiotic-resistant *Acinetobacter baumannii* clinical isolates are killed by the green tea polyphenol (−)-epigallocatechin-3-gallate (EGCG). *Clinical Microbiology & Infection*, 15, 341–346.

Pannek, S., Higgins, P.G., Steinke, P., Jonas, D., Akova, M., Bohnert, J.A. et al. (2006) Multidrug efflux inhibition in *Acinetobacter baumannii*: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. *Journal of Antimicrobial Chemotherapy*, 57, 970–974.

Patridge, E., Gareiss, P., Kinch, M.S. & Hoyer, D. (2016) An analysis of FDA-approved drugs: natural products and their derivatives. *Drug Discovery Today*, 21, 204–207.

Pendleton, J.N., Gorman, S.P. & Gilmore, B.F. (2013) Clinical relevance of the ESKAPE pathogens. *Expert Review of Anti-Infective Therapy*, 11, 297–308.

Rakholiya, K.D., Kaneria, M.I.J. & Chanda, S.V. (eds.) (2013) Medicinal plants as alternative sources of therapeutics against multidrug-resistant pathogenic microorganisms based on their antimicrobial potential and synergistic properties, 1st edition. Cambridge, MA: Academic Press.

Regueira, M.S., Tintino, S.R., da Silva, A.R.P., Costa, M.d.S., Boligon, A.A., Matias, E.F.F. et al. (2017) Seasonal variation of Brazilian red propolis: antibacterial activity, synergistic effect and phytochemical screening. *Food and Chemical Toxicology*, 107, 572–580.

Rondevaldova, J., Hummelova, J., Tauchen, J. & Kokoska, L. (2018) In vitro antibiostaphylococcal synergistic effect of isoflavone metabolite demethyltaxesin with amoxicillin and oxacillin. *Microbial Drug Resistance*, 24, 24–29.

Santajit S. & Indrawattana N. (2016) Mechanisms of antimicrobial resistance in ESKAPE pathogens. *BioMed Research International*, 2016, 1–8. http://dx.doi.org/10.1155/2016/2475067

Sudano Roccaro, A., Blanco, A.R., Giuliano, F., Rusciano, D. & Enea, V. (2004) Epigallocatechin-gallate enhances the activity of tetracycline in staphylococci by inhibiting its efflux from bacterial cells. *Antimicrobial agents and chemotherapy*, 48, 1968–1973.

Taccconelli, E. (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery and development of new antibiotics. https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/

The European Committee on Antimicrobial Susceptibility Testing (2020) Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0. http://www.eucast.org

WHO (2018) Antibiotic resistance. https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance

Zhao, W.-H., Hu, Z.-Q., Hara, Y. & Shimamura, T. (2002) Inhibition of penicillinase by epigallocatechin gallate resulting in restoration of antibacterial activity of penicillin against penicillinase-producing *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy*, 46, 2266–2268.

Zhao, W.H., Hu, Z.Q., Okubo, S., Hara, Y. & Shimamura, T. (2001) Mechanism of synergy between epigallocatechin gallate and...
beta-lactams against methicillin-resistant *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy*, 45, 1737–1742.

Zhen, X., Lundborg, C.S., Sun, X., Hu, X. & Dong, H. (2019) Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review. *Antimicrobial Resistance & Infection Control*, 8, 137–160.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Buchmann, D., Schultze, N., Borchardt, J., Bötcher, I., Schaufler, K. & Guenther, S. (2022) Synergistic antimicrobial activities of epigallocatechin gallate, myricetin, daidzein, gallic acid, epicatechin, 3-hydroxy-6-methoxyflavone and genistein combined with antibiotics against ESKAPE pathogens. *Journal of Applied Microbiology*, 132, 949–963. [https://doi.org/10.1111/jam.15253](https://doi.org/10.1111/jam.15253)